coverage and introduced innovative products like the DexCom Smart Basal. Despite these achievements, challenges in managing gross margins and quality issues with the G7 sensor deployment were ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Dexcom Inc. executives may have thought a $30 million beat ... following issues with its G7 sensor, which management said have been largely resolved.

Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

After dealing with a deployment issue with glucose monitors earlier this year, interim CEO Jake Leach said improving customer ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...

DexCom Inc (DXCM) reports a robust 22% increase in worldwide revenue, driven by expanded CGM access and strategic market ...

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...